Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-002366
Filing Date
2025-01-30
Accepted
2025-01-30 16:27:19
Documents
2
Period of Report
2025-01-30

Document Format Files

Seq Description Document Type Size
1 form3-01302025_090115.html 3  
1 form3-01302025_090115.xml 3 6016
2 ex24-01302025_090115.htm EX-24 6936
  Complete submission text file 0001415889-25-002366.txt   14437
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Issuer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O AMUNIX PHARMACEUTICALS, INC. 2 TOWER PLACE, #1100 SOUTH SAN FRANCISCO CA 94080
Business Address
Brush James (Reporting) CIK: 0001865123 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-42490 | Film No.: 25574104